Sanjiv Patel, MD
Family Medicine · Binghamton, NYNPI 1861564999
Payments from drug & device makers
Across 641 payments — averaging $64.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$34K
- Novo Nordisk$3K
- AstraZeneca$1K
- GSK$514
- Pfizer$335
- Takeda Pharmaceuticals U.S.A., Inc.$247
- plus $1K from 22 others
What the payments were for
- Consulting fees$1,1383%
- Speaking & faculty fees$27,96368%
- Travel & lodging$1190%
- Food & beverage$11,86929%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 242 | $34,399 |
| Novo Nordisk | 210 | $2,979 |
| AstraZeneca | 34 | $1,326 |
| GSK | 32 | $514 |
| Pfizer | 28 | $335 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $247 |
| Lilly USA, LLC | 14 | $197 |
| Amgen | 11 | $170 |
| Astellas Pharma US Inc | 10 | $151 |
| Johnson & Johnson | 2 | $138 |
| Boehringer Ingelheim | 11 | $127 |
| Abbott | 2 | $120 |
| Kowa Pharmaceuticals America, Inc. | 5 | $64 |
| Bayer | 3 | $61 |
| Amarin Pharma, Inc. | 2 | $36 |
| Corcept Therapeutics | 2 | $35 |
| Merck | 1 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $33 |
| Novartis | 1 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
| Vyera Pharmaceuticals, LLC | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
| Radius Health, Inc. | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,161 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 145 | $137,620 |
| OzempicSemaglutide | 101 | $118,487 |
| RybelsusSemaglutide | 73 | $98,949 |
| FarxigaDapagliflozin Propanediol | 75 | $78,606 |
| VraylarCariprazine Hcl | 40 | $62,966 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $48,187 |
| SynjardyEmpagliflozin/Metformin Hcl | 50 | $48,133 |
| Tresiba Flextouch U-200Insulin Degludec | 56 | $46,671 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $45,329 |
| JardianceEmpagliflozin | 22 | $35,093 |
| XareltoRivaroxaban | 25 | $29,784 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $25,616 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 22 | $22,884 |
| CreonLipase/Protease/Amylase | 22 | $21,529 |
| LinzessLinaclotide | 23 | $17,458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,979 | $217,437174 claims |
| PfizerEliquis | $335 | $137,620145 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,326 | $135,061155 claims |
| Boehringer IngelheimSynjardy, Jardiance, Synjardy Xr | $127 | $106,11094 claims |
| AbbVieVraylar, Creon, Linzess | $34,399 | $101,95385 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $514 | $67,071103 claims |
| Johnson & JohnsonXarelto | $138 | $29,78425 claims |
| Astellas Pharma US IncMyrbetriq | $151 | $14,58424 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $247 | $10,95419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in Binghamton
- Frank EderBinghamton$46.2M
- Matthew DavisRochester$76.6M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.